Eva Golenko
PerkinElmer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eva Golenko.
BioTechniques | 2005
Scott Kuzdzal; Mary F. Lopez; Alvydas Mikulskis; Eva Golenko; Joseph L. DiCesare; Eric Denoyer; Wayne F. Patton; Richard Ediger; Lisa Sapp; Tillmann Ziegert; Suzanne Ackloo; Michael R. Wall; David P. Mannion; Guy della Cioppa; Gershon M. Wolfe; David A. Bennett; Simon Melov
Peptides and proteins have been associated with many disease states such as cancers, diabetes, neurological and cardiovascular diseases [1-4]. Despite the limited success of a handful of biomarkers, most diseases lack sensitive and specific biomarkers. One of the most successful biomarkers, Prostate Specific Antigen (PSA) has a fairly high false-positive rate and very low clinical sensitivity (~25%).
International Review of Neurobiology | 2004
Mary F. Lopez; Simon Melov; Felicity Johnson; Nicole Nagulko; Eva Golenko; Scott Kuzdzal; Suzanne Ackloo; Alvydas Mikulskis
Publisher Summary The chapter discusses the proteomic analysis of mitochondrial proteins. Mitochondria play a central role in multiple cellular processes. In addition, mitochondrial dysfunction has been implicated in the cause of numerous diseases and disorders, including defects in energy metabolism, alzheimers and parkinsons diseases, cancer, type 2 diabetes, osteoarthritis, cardiovascular disease, and many drug side effects. A detailed map of the mitochondrial proteome, providing information on identity, function, and protein-protein interactions, would help to understand the complex mechanisms of the cellular function and disease. The rapid evolution of mass spectrometry (MS) based tools in conjunction with protein purification methods, such as 1-D gels, 2-D gels, fractionation techniques, and liquid chromatography allowed the development of mitochondrial protein maps. Numerous researchers have developed mouse models of human mitochondrial diseases by using homologous recombination. The descriptive proteomics techniques, such as mitochondrial protein maps and the functional proteomics techniques, such as (1) protein-protein interactions, (2) post-translational modifications, (3) proteomic expression profiling, and (4) differential protein expression studies using protein arrays, have helped in proteomic analysis. Differentially expressed mitochondrial and associated proteins can be identified by 2-D gel/orthogonal MALDI-TOF peptide mass fingerprinting. Future studies will undoubtedly correlate genomic, proteomic, and array data in an effort to more clearly elucidate the molecular mechanisms of mitochondria and ultimately, the whole cells.
Microarrays : optical technologies and informatics. Conference | 2001
Karl Edwin Adler; Mary C. Tyler; Alvydas Mikulskis; Mike O'Malley; Jeff J. Broadbent; Eva Golenko; Andrew Johnson; Steve Lott; Anis H. Khimani; Mark N. Bobrow
Increased sensitivity for differential mRNA expression analysis on microarrays is rapidly becoming a serious need as the technology matures. Current techniques using direct cyanine labeled targets are effective for expression analysis of abundant mRNA sources but have limited utility for analysis where mRNA quantities are limited. Tyramide signal amplification (TSATM) applied to microarray detection provides dramatic improvements in sensitivity, allowing the reduction of sample sizes by as much as 200-fold. The technique includes hapten labeling of two separate RNA populations, microarray hybridization and detection of each hapten with sequential signal amplification steps. The system uses fluorescein and biotin nucleotide analogs as the hapten pair. Hybridized fluorescein and biotin labeled targets are sequentially reacted with horseradish peroxidase and cyanine 3 and cyanine 5 tyramides, resulting in the numerous depositions of these fluorophors on the array. Differential gene expression analysis of LNCaP and PC3 prostate cancer cell lines using one microgram of total RNA and TSA detection, indicates good correlation with results obtained starting with 100 micrograms ((mu) g) of total RNA in a conventional cyanine 3 and cyanine 5 nucleotide analog labeling and detection system (i.e., the direct method).
Clinical Chemistry | 2005
Mary F. Lopez; Alvydas Mikulskis; Scott Kuzdzal; David A. Bennett; Jeremiah F. Kelly; Eva Golenko; Joseph L. DiCesare; Eric Denoyer; Wayne F. Patton; Richard Ediger; Lisa Sapp; Tillmann Ziegert; Christopher Lynch; Susan Kramer; Gordon Whiteley; Michael R. Wall; David P. Mannion; Guy della Cioppa; John S. Rakitan; Gershon M. Wolfe
Clinical Chemistry | 2007
Mary F. Lopez; Alvydas Mikulskis; Scott Kuzdzal; Eva Golenko; Emanuel F. Petricoin; Lance A. Liotta; Wayne F. Patton; Gordon Whiteley; Kevin P. Rosenblatt; Prem Gurnani; Animesh Nandi; Samuel Neill; Stuart Cullen; Martin O’Gorman; David Sarracino; Christopher Lynch; Andrew Johnson; William Mckenzie; David A. Fishman
BioTechniques | 2005
Anis H. Khimani; Abner M. Mhashilkar; Alvydas Mikulskis; Michael Paul O'malley; Jennifer Liao; Eva Golenko; Pat Mayer; Sunil Chada; Jeffrey B. Killian; Steven T. Lott
Journal of Chromatography A | 2007
Venkateswarlu Panchagnula; Alvydas Mikulskis; Linan Song; Yang Wang; Mei Wang; Tanya Knubovets; Elaine Scrivener; Eva Golenko; Ira S. Krull; Michael Schulz; Heinz-Emil-Hauck; Wayne F. Patton
Archive | 2005
Wayne F. Patton; Alvydas Mikulskis; Eva Golenko
Proteomics | 2007
Chenwei Liu; Nancy Shea; Sally Rucker; Linda Harvey; Paul Russo; Richard G. Saul; Mary F. Lopez; Alvydas Mikulskis; Scott Kuzdzal; Eva Golenko; David A. Fishman; Eric C. Vonderheid; Susan Booher; Edward W. Cowen; Sam T. Hwang; Gordon Whiteley
Proteomics | 2003
Mary F. Lopez; Alvydas Mikulskis; Eva Golenko; Klaus Herick; Carole A. Spibey; Ian Taylor; Mark N. Bobrow; Peter Jackson